Drafting Regulatory Effort Covenants and Long Stop Extensions in Divestments
Draft regulatory effort covenants with explicit remedy caps, automatic tolling extensions, and escrow-backed reverse break fees to enforce deal certainty.
Phase Two Investigations
Meaning
In-depth administrative inquiries conducted by competition authorities assess proposed mergers and corporate acquisitions that threaten to significantly impede market competition. Antitrust regulators initiate phase two investigations after initial preliminary screenings identify plausible anticompetitive outcomes, such as unilateral price increases, tacit collusion or vertical customer foreclosure. This investigative stage halts transaction progression, forcing deal partners to submit comprehensive commercial documentation, respond to broad economic subpoenas and endure detailed market testing.
Resolving these extended proceedings requires negotiating binding structural divestitures or accepting a formal administrative prohibition order against the deal.
Evidentiary Burden
Regulators subject merging companies to extensive documentary discovery, demanding millions of internal corporate communications and extensive operational datasets. During phase two investigations, economic analysts test market concentration metrics, diversion ratios and structural barriers to entry within precisely defined relevant product markets. Third-party market participants, including direct competitors, downstream customers and key input suppliers, submit confidential testimony regarding the competitive impact of the proposed business combination.
The target and buyer produce internal financial modeling, executive presentations and customer win-loss records to prove that new market entrants or countervailing buyer power will restrain post-closing pricing power.
Remedy Formulation
Merging parties facing significant competitive concerns propose binding operational commitments to prevent an outright deal veto. When evidence collected during phase two investigations indicates market harm, parties explore structural remedies centered on standalone business divestitures. Acquirers must identify suitable buyers with the financial capacity and industrial experience to operate divested assets as viable going concerns.
If parties propose behavioral remedies involving non-discriminatory supply agreements, competition authorities frequently reject them due to long-term monitoring costs. Failure to reach agreement on acceptable remedies prompts regulators to issue formal prohibition decisions that permanently block the transaction.
Procedural Perimeter
Authority to conduct in-depth reviews remains confined to business concentrations that satisfy statutory turnover or asset thresholds established in national competition statutes. Transactions cleared unconditionally during preliminary phase one reviews do not face phase two investigations, leaving parties free to close their sale. The inquiry terminates when merging parties choose to terminate the acquisition agreement rather than defend an expensive, uncertain administrative process.
Once an investigation closes with a prohibition or formal remedy clearance, competition authorities monitor divestiture implementation through appointed independent monitoring trustees. Parties challenging a regulatory veto take their claims to appellate courts, where judicial review focuses on administrative procedural fairness and legal interpretation rather than fresh market analysis. Phase two reviews fundamentally alter deal economics by increasing advisory fees and consuming executive bandwidth throughout months of procedural uncertainty.